158 related articles for article (PubMed ID: 32231867)
1. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Georganaki M; Ramachandran M; Tuit S; Núñez NG; Karampatzakis A; Fotaki G; van Hooren L; Huang H; Lugano R; Ulas T; Kaunisto A; Holland EC; Ellmark P; Mangsbo SM; Schultze J; Essand M; Tugues S; Dimberg A
Oncoimmunology; 2020; 9(1):1730538. PubMed ID: 32231867
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
3. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
4. The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma.
Orecchini E; Belladonna ML; Pallotta MT; Volpi C; Zizi L; Panfili E; Gargaro M; Fallarino F; Rossini S; Suvieri C; Macchiarulo A; Bicciato S; Mondanelli G; Orabona C
Oncoimmunology; 2023; 12(1):2170095. PubMed ID: 36733497
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
6. An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN; Huang X; Vredevoogd DW; de Bruijn B; Traets JJH; Ibáñez-Molero S; Schieven SM; van Vliet A; Krijgsman O; Kuilman T; Pozniak J; Loayza-Puch F; Terry AM; Müller J; Logtenberg MEW; de Bruijn M; Levy P; Körner PR; Goding CR; Schumacher TN; Marine JC; Agami R; Peeper DS
Cell Rep Med; 2023 Feb; 4(2):100941. PubMed ID: 36812891
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
[TBL] [Abstract][Full Text] [Related]
8. The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.
Endo R; Nakamura T; Kawakami K; Sato Y; Harashima H
Sci Rep; 2019 Aug; 9(1):11335. PubMed ID: 31383907
[TBL] [Abstract][Full Text] [Related]
9. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Li A; Barsoumian HB; Schoenhals JE; Caetano MS; Wang X; Menon H; Valdecanas DR; Niknam S; Younes AI; Cortez MA; Welsh JW
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):903-912. PubMed ID: 30905636
[TBL] [Abstract][Full Text] [Related]
10. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.
Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D
Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594
[TBL] [Abstract][Full Text] [Related]
11. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors.
Ye K; Wang K; Wang T; Tang H; Wang L; Zhang W; Jiang S; Zhang X; Zhang K
Eur J Med Chem; 2023 Mar; 250():115217. PubMed ID: 36842272
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase 1 in corneal endothelial cells limits herpes simplex virus type 1-induced acquired immune response.
Haruki T; Miyazaki D; Inata K; Sasaki S; Yamamoto Y; Kandori M; Yakura K; Noguchi Y; Touge C; Ishikura R; Touge H; Yamagami S; Inoue Y
Br J Ophthalmol; 2015 Oct; 99(10):1435-42. PubMed ID: 26142400
[TBL] [Abstract][Full Text] [Related]
14. Mutual antagonism between indoleamine 2,3-dioxygenase 1 and nuclear factor E2-related factor 2 regulates the maturation status of DCs in liver fibrosis.
Mo C; Xie S; Zhong W; Zeng T; Huang S; Lai Y; Deng G; Zhou C; Yan W; Chen Y; Huang S; Gao L; Lv Z
Free Radic Biol Med; 2020 Nov; 160():178-190. PubMed ID: 32771520
[TBL] [Abstract][Full Text] [Related]
15. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
[TBL] [Abstract][Full Text] [Related]
16. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
Zhai L; Ladomersky E; Lauing KL; Wu M; Genet M; Gritsina G; Győrffy B; Brastianos PK; Binder DC; Sosman JA; Giles FJ; James CD; Horbinski C; Stupp R; Wainwright DA
Clin Cancer Res; 2017 Nov; 23(21):6650-6660. PubMed ID: 28751450
[No Abstract] [Full Text] [Related]
17. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
18. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Hennequart M; Pilotte L; Cane S; Hoffmann D; Stroobant V; Plaen E; Van den Eynde BJ
Cancer Immunol Res; 2017 Aug; 5(8):695-709. PubMed ID: 28765120
[TBL] [Abstract][Full Text] [Related]
19. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
20. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
